- Title: Longitudinal detection of SARS-CoV-2-specific antibody responses with different
 serological methods
- 3 **Running head:** Kinetics of anti-SARS-CoV-2 antibodies
- 4 Authors: Petra Emmerich^{1,2}, Ronald von Possel^{1,2}, Christoph Josef Hemmer², Carlos Fritzsche²,
- 5 Hilte Geerdes-Fenge², Babett Menge³, Claudia Messing³, Viola Borchardt-Lohölter^{3,*}, Christina
- 6 Deschermeier⁴⁺, Katja Steinhagen³⁺

7 Affiliations:

- ¹ Department of Virology, Bernhard Nocht Institute for Tropical Medicine, WHO Collaborating Centre
 for Arbevirus and Hemorrhagic Fever Peteronee and Pesearch, Hemburg, Cormany.
- 9 for Arbovirus and Hemorrhagic Fever Reference and Research, Hamburg, Germany
- 10 ² Department of Tropical Medicine and Infectious Diseases, Center for Internal Medicine, University of
- 11 Rostock, Rostock, Germany
- 12 ³ Institute for Experimental Immunology, affiliated with EUROIMMUN Medizinische Labordiagnostika
- 13 AG, Luebeck, Germany
- ⁴ Department for Infectious Disease Diagnostics, Bernhard Nocht Institute for Tropical Medicine,
 Hamburg, Germany
- 16 * Corresponding author: Viola Borchardt-Lohölter, EUROIMMUN Medizinische Labordiagnostika AG,
- Seekamp 31, 23560 Luebeck, Germany, v.borchardt-lohoelter@euroimmun.de, +49 451 20321619.
 + These authors contributed equally.
- 18 Keywords: antibodies, COVID-19, ELISA, immunofluorescence, SARS-CoV-2, serology

19 ABSTRACT

- 20 Serological testing for anti-SARS-CoV-2 antibodies is used to detect ongoing or past SARS-CoV-2
- 21 infections. To study the kinetics of anti-SARS-CoV-2 antibodies and to assess the diagnostic
- 22 performances of eight serological assays, we used 129 serum samples collected on known days
- post symptom onset (dpso) from 42 patients with PCR-confirmed COVID-19 and 54 serum
- samples from healthy blood donors, and children infected with seasonal coronaviruses.
- The sera were analyzed for the presence of IgG, IgM and IgA antibodies using indirect immunofluorescence testing (IIFT) based on SARS-CoV-2-infected cells. They were further tested for antibodies against the S1 domain of the SARS-CoV-2 spike protein (IgG, IgA) and
- against the viral nucleocapsid protein (IgG, IgM) using ELISA.
- 29 The assay specificities were 94.4%-100%. The sensitivities varied largely between assays,
- 30 reflecting their respective purposes. The sensitivities of IgA and IgM assays were highest
- between 11 and 20 dpso, whereas the sensitivities of IgG assays peaked between 20 and 60
- 32 dpso.
- 33 IIFT showed highest sensitivities due to the use of the whole SARS-CoV-2 as substrate and
- 34 provided information whether or not the individual has been infected with SARS-CoV-2. ELISAs
- 35 provided further information about both the prevalence and concentration of specific antibodies
- against selected antigens of SARS-CoV-2.

37 INTRODUCTION

In the current pandemic, direct pathogen detection via reverse transcription and polymerase 38 39 chain reaction amplification as well as real-time detection (real-time RT-PCR) is the gold 40 standard for SARS-CoV-2 detection and enables early identification of acute SARS-CoV-2 41 infections. Serological testing for anti-SARS-CoV-2 antibodies is used to confirm ongoing or past 42 infections with SARS-CoV-2. The detection of antibodies enables confirmation of SARS-CoV-2 43 infection in patients with typical symptoms and in suspected (asymptomatic) cases. Analysis of anti-SARS-CoV-2 antibodies is typically performed at an advanced stage of infection and thus 44 45 expands the time frame for COVID-19 diagnostics.

- Seroconversion of anti-SARS-CoV-2 antibodies can occur at different points in time after virus contact^{1,2}. The features of immune responses to SARS-CoV-2 infections vary significantly between individuals³, especially regarding the kinetics, immunoglobulin classes and antigen specificity. In the majority of COVID-19 patients, anti-SARS-CoV-2 antibodies are detectable within two weeks of infection^{4–6}. Usually, specific IgM and IgA antibodies are detectable earlier than specific IgG antibodies^{5,7,8}. In individual cases, anti-SARS-CoV-2 antibodies are either only detectable more than four weeks after onset of symptoms or not at all due to generally absent
- 53 antibody secretion⁸⁻¹⁰.
- Anti-SARS-CoV-2 antibodies target different structural proteins of SARS-CoV-2. The main 54 55 immunogens are the spike and nucleocapsid proteins. The highly immunogenic S1 domain of the 56 spike protein of SARS-CoV-2 is a major target for neutralizing antibodies and is being used as the antigen in many serological assays¹¹. The immunologically relevant receptor binding domain 57 58 (RBD) represents another important target antigen for virus-neutralizing antibodies¹². The nucleocapsid protein (NCP) of SARS-CoV-2 is the antigen with the strongest immune dominance 59 among *Coronaviridae*¹³ and contains diagnostically relevant epitopes of SARS-CoV-2. Previous 60 studies suggested heterogeneous binding antibody responses to S1/RBD and NCP viral 61 antigens¹⁴, and hence the presence of antibodies against one protein of SARS-CoV-2 does not 62 necessarily coincide with the presence of antibodies against another. 63
- 64 Current research is determined to illuminate kinetics of the humoral immune response against 65 SARS-CoV-2, potentially providing guidance on when to use serological tests effectively for screening or monitoring of the infection. Results of serological tests can provide answers to 66 67 important epidemiological, clinical and virological questions concerning SARS-CoV-2, for 68 instance, on the traceability of infection chains and the role of asymptomatic or presymptomatic 69 transmission. Moreover, exact determination of the course of concentration of IgG antibodies 70 against SARS-CoV-2 before and after vaccination can provide valuable information on the 71 effectiveness of vaccination.
- 72 Currently, knowledge about SARS-CoV-2 antibody persistence is scarce, although it would help
- to understand the possible role of humoral immunity in the protection against reinfection. The
- aim of this research was to study the kinetics of antibodies against SARS-CoV-2 and to explore
- 75 the characteristic features of eight serological assays.

76 **METHODS**

77 Human serum samples

- 78 Panel A comprised 82 sequential and single serum samples from 25 German patients (Table 1).
- Infection with SARS-CoV-2 was confirmed by PCR¹⁵ by regional health authorities. These
 patients had mild to moderate COVID-19 symptoms.
- 81 Panel B comprised 47 sequential and single serum samples from 17 German patients (Table 1).
- 82 Infection with SARS-CoV-2 was confirmed by PCR using the Allplex 2019-nCoV Assay (Seegene
- 83 Inc., Seoul, Korea). These patients required hospitalization.
- 84 All patient samples were also serologically precharacterized by IIFT.
- Panel C comprised serum samples taken before August 2019 from 42 healthy German blooddonors (Table 1).
- 87 Panel D comprised serum samples taken between January and March 2020 from twelve German
- children (Table 1) positive for IgG against seasonal coronaviruses (e.g. HCoV 229-E) by indirect
- 89 immunofluorescence testing (IIFT, for research use only).
- 90

91 Detection of anti-SARS-CoV-2 antibodies

- 92 The detection of the antibodies against SARS-CoV-2 (genus: *Betacoronavirus*, family: 93 *Coronaviridae*) using IIFT was performed with anti-IgG-, anti-IgA- and anti-IgM-FITC-labelled 94 secondary antibodies on infected Vero E6 cells fixed in acetone-methanol^{16,17}. Sample dilutions 95 from 1:20 to 1:80 were screened. In case of a positive result, it was titrated to the final titer. An 96 immunofluorescence signal at titers \geq 1:20 was rated as positive and otherwise as negative.
- 96 immunofluorescence signal at titers ≥1:20 was rated as positive and otherwise as negative.
 97 Samples were further tested for the presence of antibodies against SARS-CoV-2 with five
- 98 enzyme-linked immunosorbent EUROIMMUN assays (ELISA, from Medizinische 99 Labordiagnostika AG, Luebeck, Germany). All ELISAs apply viral antigens recombinantly expressed in human cells. The Anti-SARS-CoV-2 ELISA (IgG) and Anti-SARS-CoV-2 ELISA (IgA) 100 are based on the S1 domain of the spike protein of SARS-CoV-2 as antigen, including the 101 immunologically relevant receptor binding domain (RBD), to detect anti-SARS-CoV-2 IgG and 102 IgA antibodies, respectively. The Anti-SARS-CoV-2 QuantiVac ELISA (IgG) was used for 103 104 quantitative detection of anti-SARS-CoV-2 IgG antibodies by means of a 6-point calibration curve. The Anti-SARS-CoV-2 NCP ELISA (IgG) and Anti-SARS-CoV-2 NCP ELISA (IgM) are based 105 106 on a modified nucleocapsid protein (NCP) as antigen to detect anti-SARS-CoV-2 IgG and IgM 107 antibodies, respectively. ELISA results were evaluated as recommended by the manufacturer. 108 Borderline results were reported but excluded from the subsequent analyses, since they do not allow secure evaluation and are subjected to retesting by means of other diagnostic methods 109 110 and/or serological investigation of a follow-up sample in laboratory practice.
- 111 The detection of SARS-CoV-2-specific antibody responses was also investigated with respect to
- the infection phase. Because the diagnostic window for serological testing opens several days after pathogen contact, only samples taken later than ten dpso were considered. The phases
- 114 were split in 11-20 dpso (early phase of infection; n samples in panel A: 10, panel B: 19), 21-60
- dpso (intermediate phase of infection; n samples in panel A: 28, panel B: 3) and >60 dpso (past
- 116 infection; n samples in panel A: 43, panel B: 6, Table 1).
- 117 The overall agreement between qualitative results obtained with the Anti-SARS-CoV-2 ELISA
- 118 (IgG) and Anti-SARS-CoV-2 QuantiVac ELISA (IgG) was calculated, their degree of agreement was
- 119 quantified using Cohen's κ including borderline results¹⁸, and the statistical association between
- 120 results was described using Pearson correlation and 95% confidence intervals as determined by
- 121 Clopper-Pearson interval.

122 **RESULTS**

123 The sensitivities varied largely between assays (Table 2). The IIFT revealed positive results for 124 anti-SARS-CoV-2 IgG, IgA and IgM antibodies in 94.6%, 72.9% and 65.9% of the patient samples,

respectively. The ELISAs detected specific antibodies against S1 IgG and IgA in 75.8% and 80.3%

126 of the patient samples, respectively. Anti-SARS-CoV-2 IgG and IgM antibodies against NCP were

- detected in 82.0% and 19.8% of the patient samples, respectively. The specificity was 100% by
- 128 IIFT, Anti-SARS-CoV-2 ELISA (IgG, IgA) and Anti-SARS-CoV-2 NCP ELISA (IgM), while the four
- remaining assays reached specificities between 92.9% and 97.6%. Cross-reactivities were not
- 130 observed.
- 131

The sensitivities of IgA and IgM assays were highest in the early phase of infection, while
positive results for IgG antibodies occurred most often in the intermediate phase (Table 3,
Figure 1).

- 135 Positive results for anti-SARS-CoV-2 IgG antibodies against S1 reached a peak during the
- intermediate phase of infection. In contrast, positive results for anti-SARS-CoV-2 IgA antibodiesas measured by IIFT showed an initial peak followed by a pronounced decrease after 60 dpso.
- 137 as incastred by In 1 showed an initial peak followed by a pronounced decrease after 50 upso.
 138 During the course of infection, the number of positive results for anti-SARS-CoV-2 IgM
 139 antibodies dropped as measured both by ELISA and UET.
- 139 antibodies dropped as measured both by ELISA and IIFT.
- 140 In the early phase of infection (11-20 dpso), IgG and IgA antibodies against S1 of SARS-CoV-2 141 were detected in 70.4% and 88.9% of the samples (n=29), respectively, while IgG and IgM
- antibodies against NCP were detected in 86.2% and 50%, respectively. The IIFT detected SARS-
- 143 CoV-2 specific IgG, IgA and IgM antibodies in 96.6%, 93.1% and 96.6% of the samples,144 respectively.
- 145 In the intermediate phase of infection (21-60 dpso), IgG and IgA antibodies against S1 of SARS-
- 146 CoV-2 were detected in 93.3% and 82.8% of the samples (n=31), respectively, while IgG and IgM
- antibodies against NCP were detected in 96.8% and 12.9%, respectively. The IIFT detectedspecific IgG, IgM and IgA antibodies in 100%, 87.1% and 100%, respectively.
- 149 In the late phase of infection (>60 dpso), IgG and IgA antibodies against S1 of SARS-CoV-2 were
- detected in 85.1% and 80.5% of the samples (n=49), respectively, while IgG and IgM antibodies
 against NCP were detected in 81.4% and 0%, respectively. The IIFT detected specific IgG, IgA
- and IgM antibodies in 98%, 44.9% and 30.6%, respectively.
- 153 Overall, in samples taken later than 10 dpso, IgG and IgA antibodies against S1 of SARS-CoV-2 154 were detected in 83.7% and 83.5% of the samples (n=109), respectively, while IgG and IgM
- were detected in 83.7% and 83.5% of the samples (n=109), respectively, while IgG and IgM antibodies against NCP were detected in 87.4% and 17%, respectively. The IIFT detected specific
- 156 IgG, IgA and IgM antibodies in 98.2%, 73.4% and 64.2%, respectively.
- 157
- 158 The Anti-SARS-CoV-2 QuantiVac ELISA (IgG) showed a high total agreement (98.9%, Table 4), an
- almost perfect degree of agreement (κ =0.93, 95% confidence interval: [0.87, 0.98]) of qualitative
- results with the Anti-SARS-CoV-2 ELISA (IgG) as well as a high correlation (r=0.98, p<0.001)
- 161 between (semi)quantitative results (Figure 2).

162 **DISCUSSION**

163 The aim of this research was to study long-term kinetics of antibodies against SARS-CoV-2 and to 164 assess the characteristic features of different serological methods. We present findings of the 165 temporal profiles of IgG, IgA and IgM antibody responses against SARS-CoV-2 determined in sera

- 166 from patients with mild to severe COVID-19 by means of eight serological assays.
- 167 The sensitivities varied between assays and phases of infection but corroborated that the 168 different substrates used in the assays serve different purposes. Due to the use of the whole
- 169 SARS-CoV-2 as substrate and the precharacterization by IIFT, the IgG IIFT showed, overall, the
- highest sensitivity (94.6%) when testing all patient samples, independent of the infection phase
- 171 (Table 1).
- The ELISAs, in contrast, provide information about the prevalence of specific antibodies against
 selected antigens of SARS-CoV-2. Hence, lower sensitivities of the S1-specific ELISAs compared
- to the NCP-specific ELISA probably reflect the known fact that not all infected individuals
- produce antibodies against the S1 domain of SARS-CoV-2¹⁰. Importantly, previous research
- showed that responses of specific IgG against S1 and NCP may be heterogeneous between
- 177 individuals, time-delayed and do not always coincide with each other^{8,12,14}. In the present panels,
- the prevalence of specific IgG antibodies against NCP in the early phase of infection was higher
- than that against S1 (Table 2). However, the findings of the current study do not support
- 180 previous research by Herroelen et al who undertook a comparative evaluation of commercial
- 181 SARS-CoV-2 serological assays and observed no clear differences in the seroconversion kinetics
- of antibodies targeting SARS-CoV-2 S and N protein epitopes between severe and milder SARS-CoV-2 infections.
- Exclusively in the early phase of infection, the prevalence of specific IgA antibodies against S1 was higher than that of specific IgG antibodies against NCP as well as S1. This observation reflects that of Okba et al¹. However, it is contrary to a previous study that showed a higher sensitivity of the Anti-SARS-CoV-2 IgG compared to the Anti-SARS-CoV-2 IgA ELISA in patient samples taken later than fourteen dpso¹⁹, whereby the discrepancy might be due to heterogeneous definitions regarding the early phase of infection.
- The IgA IIFT showed a pronounced decrease in the antibody detection rate after 60 dpso, which was not observed for the IgA ELISA (Table 2). A possible explanation for this might be that the IgA antibody response against the S1 protein largely remains constant, while the production of
- 193 IgA antibodies against other antigens of SARS-CoV-2 decreases.
- 194 More patients were seropositive for IgM by IIFT than by ELISA (Table 1, Table 2), which could be accounted for by a low sensitivity of the NCP IgM ELISA, warranting further investigations. 195 196 However, the continuously low sensitivity of the NCP-specific IgM ELISA (Table 2) is in 197 accordance with previous results indicating a sensitivity of 55% at week three to four after disease onset²⁰. Liu et al also observed a higher sensitivity of an ELISA based on the spike 198 protein compared to an NCP-based ELISA for detection of IgM antibodies⁸. Two months after 199 symptom onset, we observed a decline in the sensitivity of both IgM-specific assays (Table 2). 200 Independent of the serological method, the two IgM-specific assays reached maximal 201 sensitivities between 11-20 dpso (Table 2) and could therefore especially be applied to detect 202 antibodies in samples taken during the early phase of infection. If patients develop specific IgM 203 204 against NCP, these antibodies seem to be present for only a short time during the early phase of infection. A sharp decline in the IgM prevalence is to be expected because isotype switching of 205 206 virus-specific B-cells from IgM to IgG antibody production causes a decline in circulating IgM²¹.
- 207 The facts that SARS-CoV-2-specific IgM is detected mostly in the early infection phase but only in

rare cases²² invites the question whether all isotypes should be measured during
 serodiagnostics.

210

The agreement analysis revealed a very high correlation between results obtained with the Anti-211 SARS-CoV-2 ELISA (IgG) and the QuantiVac ELISA (IgG). The two samples that showed 212 213 inconsistent qualitative results between these assays (Table 3, Figure 2) were taken relatively 214 early and late (7 and 116 dpso) in the course of the disease. An explanation for these inconsistencies might be that the assays were incubated using the same aliquot but on different 215 days, hence the experimental conditions might have differed slightly. Another reason might be 216 that the artificial division between positive and negative results does not match the natural 217 218 range of activity of some samples.

219

220 In general, the use of cells infected with the whole SARS-CoV-2 as substrate has the great 221 advantage of obtaining a high sensitivity due to presence of the complete antigenic spectrum, as 222 evident in the present IIFT results. This is, however, linked to the disadvantage that a positive 223 IIFT result does not allow for a conclusion on the molecular identity of the antigen(s) binding the 224 antibody. In contrast, recombinant cell substrates used in the ELISA technique are ideally suited 225 for the detection and precise identification of antibodies against selected proteins of SARS-CoV-2 such as S1/RBD and NCP. During the purification required for Anti-SARS-CoV-2 NCP ELISA 226 227 production, tertiary or quaternary structured epitopes are often destroyed or weakened. 228 Nevertheless, a selective loss of reactivity does have advantages, since undesired antibody binding aside from the recombinant target protein can be suppressed. Thereby, the specificity of 229 the ELISA can be improved, which was evident in the present results. Moreover, the ELISA 230 technique has the advantage of yielding results in numeral form, which allows an objective 231 232 evaluation of results. The use of SARS-CoV-2 IIFT is (currently) reserved for specialized research 233 laboratories with high biosafety restrictions due to the handling of the full virus, and, compared 234 to other serological techniques, IIFT is less implemented in standard diagnostic laboratories.

235

The presence of anti-SARS-CoV-2 S1/RBD IgG antibodies seems to correlate with the 236 development of both virus neutralization and immunity^{1,3,23}. Previous research found that titers 237 of neutralizing antibodies were significantly correlated with the levels of anti-RBD IgG¹², and 238 RBD-specific IgG titers were suggested as a surrogate of neutralization potency against SARS-239 CoV-2 infection²⁴. Nevertheless, it is possible that a patient does not develop antibodies against 240 241 S1 of SARS-CoV-2, but only against NCP. However, this would suggest that neutralizing antibodies might not be present since binding antibodies against NCP seem to correlate to a 242 lesser degree with immunity than binding antibodies against S1/RBD²⁵. The development of 243 immunity to SARS-CoV-2 is induced both by the humoral and the cellular immune response, 244 whereby especially IgG directed against the S1 subunit of the SARS-CoV-2 spike protein and 245 246 specific long-lived T cells are of great interest, as they are suspected to play the most relevant 247 roles in virus neutralization and sustained immunity. A combination of serological tests to 248 quantify both the interferon-gamma release by SARS-CoV-2-specific T cells, stimulated by SARS-249 CoV-2 specific antigens, and the presence of anti-S1/RBD IgG antibodies will enable 250 differentiated investigation of the immune response in the progression of infection and vaccination. Especially the determination of relevant antibody concentrations will probably be 251 one of the most important instruments for determining the vaccination success, although it is yet 252 unknown how many antibodies against S1/RBD an individual must produce after vaccination to 253 254 be protected from COVID-19. Surrogate neutralization assays detect circulating neutralizing

antibodies against SARS-CoV-2 that block the interaction between the RBD of SARS-CoV-2 with
the ACE2-cell surface receptor of the human host cell, thus supporting a quick diagnostic
statement about the degree of immunity. In contrast to plaque-reduction neutralization tests,
which require handling of the virus, surrogate neutralization assays can easily be integrated in
the laboratory routine and do not require biosafety level 3 laboratories.

260

A detailed analysis of potential associations between antibody kinetics and disease severity was not performed because symptoms were not systematically recorded and the disease severity could therefore not be rated other than that patients in panel A had no or mild symptoms and patients in panel B required hospitalization. Nevertheless, the assay sensitivities were reported also for each panel separately (Table 1). Analysis of temporal profiles was performed on samples from both patient panels because the distribution of samples in the three infection phases was unbalanced between panels A and B (Table 1).

- ELISA or immunoblot techniques might be used in future to differentiate between reactivities
 against distinctive SARS-CoV-2 antigens, which might be useful for determination of biomarkers
- 270 indicative of early or late infection phases.
- 271

272 In summary, evidence of this study emphasizes that the assays have different advantages as well as intended purposes. ELISAs provide an insight into the prevalences of specific antibodies 273 274 against selected antigens of SARS-CoV-2. Due to the heterogeneity of individual antibody 275 responses, ELISA may not yield positive results for all patients but a combination of ELISAs with 276 different antigens can reduce this diagnostic gap. The three Anti-SARS-CoV-2 ELISAs that detect 277 IgG antibodies can be used to confirm pathogen contact, starting from week two of the infection, to monitor the humoral response following an acute infection confirmed by direct detection and 278 279 to detect past infections. The highly immunogenic S1 domain of the spike protein of SARS-CoV-2 is a major target for neutralizing antibodies and showed good correlation with different test 280 systems for the detection of neutralizing antibodies^{19,26,27}. IgA-specific ELISAs might further be 281 282 used to monitor the immune response in COVID-19 patients. IIFT showed highest sensitivities due to the use of the whole SARS-CoV-2 as substrate and provide information whether or not an 283 individual has been infected with SARS-CoV-2. 284

285 **Conflict of Interest**

BM, CM, VBL, KS are employees of EUROIMMUN Medizinische Labordiagnostika AG, a company
that commercializes serological assays and co-owns a patent application related to
immunoassays for the diagnosis of a SARS-CoV-2 infection.

290 Funding

PE and CD received funding from the German Federal Ministry of Education and Research (grant number: 01KI20210). The funder had no role in study design, data collection and analysis, designed to publish on proposition of the manuscript

- 293 decision to publish, or preparation of the manuscript.
- 294

289

295 Ethics Statement

The observational study has been performed in agreement with the Declaration of Helsinki. Ithas been approved by the Ethics Review Board of the University Medicine Rostock (registration

- number: A2020-0086) and the Ethics Review Board of the Medical Association Hamburg(registration number: 2020-10162-BO-ff).
- 300 The samples from healthy adults (panel C, Table 1) were collected via blood donation. Diagnostic

301 leftover samples after completion of all diagnostic measures from children (panel D, Table 1)

were collected by a routine clinical laboratory (Lübeck, Germany). All samples were processedanonymously.

304

305 Acknowledgements

The authors thank Neele Pekarek of BNITM for supporting performance of the analyses at thefacilities of the BNITM.

308 The authors thank Marieke Schulz of EUROIMMUN Medizinische Labordiagnostika AG for

- 309 supporting laboratory analysis, which was funded by EUROIMMUN Medizinische
- 310 Labordiagnostika AG, Luebeck, Germany, in accordance with Good Publication Practice (GPP3)
- 311 guidelines (<u>http://www.ismpp.org/gpp3</u>).
- All probands and patients are gratefully acknowledged for providing samples and participatingin this study.
- 314

315 Author contributions:

- 316 Petra Emmerich: Conceptualization, Investigation, Funding Acquisition, Project Administration,
- 317 Writing Review & Editing
- 318 Ronald von Possel: Investigation, Review & Editing
- 319 Christoph Hemmer: Investigation, Data curation, Review & Editing
- 320 Hilte Geerdes-Fenge: Investigation, Data curation, Review & Editing
- 321 Carlos Fritzsche: Investigation, Data curation, Review & editing
- 322 Babett Menge: Investigation, Data curation, Writing Review & Editing
- 323 Claudia Messing: Resources, Writing Review & Editing
- 324 Viola Borchardt-Lohölter: Formal analysis, Visualization, Writing Original Draft Preparation
- 325 Christina Deschermeier: Funding Acquisition, Project Administration, Review & Editing
- 326 Katja Steinhagen: Resources, Project Administration, Writing Review & Editing

327 **REFERENCES**

- Okba NMA, Müller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Specific Antibody Responses in Coronavirus Disease 2019 Patients. *Emerg Infect Dis.* 2020;26(7). doi:10.3201/eid2607.200841
- Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients
 with COVID-2019. *Nature*. 2020;581(7809):465-469. doi:10.1038/s41586-020-2196-x
- To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior
 oropharyngeal saliva samples and serum antibody responses during infection by SARS CoV-2: an observational cohort study. *Lancet Infect Dis.* 2020;20(5):565-574.
 doi:10.1016/S1473-3099(20)30196-1
- Prévost J, Gasser R, Beaudoin-Bussières G, et al. Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. *Cell reports Med.* 2020;1(7):100126.
 doi:10.1016/j.xcrm.2020.100126
- Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol*. 2020;5:1598–1607. doi:10.1038/s41564-020-00813-8
- Lippi G, Salvagno GL, Pegoraro M, et al. Assessment of immune response to SARS-CoV-2
 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence
 immunoassays. *Clin Chem Lab Med*. 2020;58(7):1156-1159. doi:10.1515/cclm-2020-0473
- 346 7. Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with
 347 COVID-19. *Nat Med*. 2020;26(6):845-848. doi:10.1038/s41591-020-0897-1
- Liu W, Liu L, Kou G, et al. Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2. *J Clin Microbiol*. March 2020.
 doi:10.1128/JCM.00461-20
- Guo L, Ren L, Yang S, et al. Profiling Early Humoral Response to Diagnose Novel
 Coronavirus Disease (COVID-19). *Clin Infect Dis*. March 2020. doi:10.1093/cid/ciaa310
- Oved K, Olmer L, Shemer-Avni Y, et al. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation.
 EClinicalMedicine. 2020;29-30. doi:10.1016/j.eclinm.2020.100651
- Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. The Role of Antibody
 Testing for SARS-CoV-2: Is There One? *J Clin Microbiol*. 2020;(April):1-7.
 doi:10.1128/JCM.00797-20
- Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological Assays
 Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral
 Immunity. *Immunity*. 2020;53(5):925-933.e4. doi:10.1016/j.immuni.2020.10.004
- Che X, Qiu L, Pan Y, et al. Sensitive and Specific Monoclonal Antibody-Based Capture
 Enzyme Immunoassay for Detection of Nucleocapsid Antigen in Sera from Patients with
 Severe Acute Respiratory Syndrome. *J Clin Microbiol*. 2004;42(6):2629 LP 2635.
 doi:10.1128/JCM.42.6.2629-2635.2004
- McAndrews KM, Dowlatshahi DP, Dai J, et al. Heterogeneous antibodies against SARS CoV-2 spike receptor binding domain and nucleocapsid with implications on COVID-19
 immunity. *JCI Insight*. 2020;5(18):1-14. doi:10.1172/jci.insight.142386
- 15. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by

- real-time RT-PCR. *Euro Surveill*. 2020;25(3):1-8. doi:10.2807/1560 7917.ES.2020.25.3.2000045
- Reisinger EC, von Possel R, Warnke P, et al. Mütter-Screening in einem COVID-19-Niedrig Pandemiegebiet: Bestimmung SARS-CoV-2-spezifischer Antikörper bei 401 Rostocker
 Müttern mittels ELISA und Immunfluoreszenz-Bestätigungstest. *Dtsch Medizinische Wochenschrift*. 2020. doi:10.1055/a-1197-4293
- Emmerich P, Murawski C, von Possel R, et al. Limited specificity of commercially available
 SARS-CoV-2 IgG ELISAs in serum samples of African origin. *Trop Med Int Heal*. 2020.
 doi:https://doi.org/10.1111/tmi.13569
- Watson PF, Petrie A. Method agreement analysis: A review of correct methodology.
 Theriogenology. 2010;73(9):1167-1179. doi:10.1016/j.theriogenology.2010.01.003
- GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment. *medRxiv*.
 2020:2020.04.23.20077156. doi:10.1101/2020.04.23.20077156
- Orth-Höller D, Eigentler A, Stiasny K, Weseslindtner L, Möst J. Kinetics of SARS-CoV-2
 specific antibodies (IgM, IgA, IgG) in non-hospitalized patients four months following
 infection. *J Infect*. 2020;(xxxx):17-19. doi:10.1016/j.jinf.2020.09.015
- Yu HQ, Sun BQ, Fang ZF, et al. Distinct features of SARS-CoV-2-specific IgA response in
 COVID-19 patients. *Eur Respir J*. 2020;56(2):7-10. doi:10.1183/13993003.01526-2020
- 389 22. Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody
 390 response to SARS-CoV-2. *Sci Transl Med.* 2021;13(577):eabd2223.
 391 doi:10.1126/scitranslmed.abd2223
- Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and kinetics of SARS-CoV-2-specific
 T cells in COVID-19 patients with acute respiratory distress syndrome. *Sci Immunol*.
 2020;5(48):1-14. doi:10.1126/SCIIMMUNOL.ABD2071
- Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular
 Immunity in COVID-19 Convalescent Individuals. *Immunity*. 2020;52(6):971-977.e3.
 doi:10.1016/j.immuni.2020.04.023
- 398 25. McAndrews KM, Dowlatshahi DP, Dai J, et al. Heterogeneous antibodies against SARS399 CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19
 400 immunity. *JCI Insight*. 2020;5(18):1-14. doi:10.1172/JCI.INSIGHT.142386
- 401 26. Streeck H, Schulte B, Kuemmerer B, et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. *Nat Commun.*403 2020;11(5829):2020.05.04.20090076. doi:10.1101/2020.05.04.20090076
- 404 27. Harvala H, Mehew J, Robb ML, et al. Convalescent plasma treatment for SARS-CoV-2
 405 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. *Euro*406 Surveill. 2020;25(28). doi:10.2807/1560-7917.ES.2020.25.28.2001260

407 **TABLES**

Panel	Age (mean±sd)	Sex (n females, n males, n unknown)	N samples in panel	N samples per patient (mean±sd, range)	Dpso (mean±sd, range)	N samples ≤10 dpso	N samples 11-20 dpso	N samples 21-60 dpso	N samples >60 dpso
A 25 patients	43.2±13.7,	17, 8, 0	82	3.3±1, [1, 5]	78.4±49.7, [10, 178]	1	10	28	43
B 17 patients	68.0±16.1,	9, 9, 0	47	2.8±1.4, [1,6]	26.1±30.8, [1, 109]	13	19	3	6
C 42 blood donors	>18, 42 unknown	0, 0, 42	42	1±0	-	-	-	-	-
D 12 children	7.8±4.2, 0 unknown	3, 7, 0	12	1±0	-	-	-	-	-

408 Table 1: Descriptive information of all panels. Dpso: days after symptom onset. Sd: standard409 deviation.

410

411

412 **Table 2: Diagnostic performance of the assays.** Sensitivities were determined based on panel

413 A (n samples = 82), panels B (n samples = 47) and panels A+B (n samples = 129). Specificities

were determined based on panel C (n samples = 42). Cross-reactivities were determined based
on panel D (n samples = 12). CI: 95% confidence interval. Borderline ELISA results were
excluded for calculation of the sensitivity and specificity.

			IIFT		ELISA								
Panel		IgG	IgA	IgM	S1 IgG	QuantiVac S1 IgG	S1 IgA	NCP IgG	NCP IgM				
	n positive	82	59	45	66	66	60	65	4				
	n borderline	-	-	-	4	5	10	6	3				
Α	n negative	0	23	37	12	11	12	11	75				
	Sensitivity	100%	72%	54.9%	84.6%	85.7%	83.3%	85.5%	5%				
	CI [%]	[95.6, 100]	[60.9, 81.3]	[43.5, 65.9]	[74.7, 91.8]	[75.9, 92.7]	[72.7, 91.1]	[75.6, 92.6]	[1.4, 12.5]				
	n positive	40	35	40	28	30	34	35	21				
	n borderline	-	-	-	1	0	2	1	0				
В	n negative	7	12	7	18	17	11	11	26				
	Sensitivity	85.1%	74.5%	85.11%	60.9%	63.8%	75.6%	76.1%	44.7%				
	CI [%]	[71.7, 93.8]	[59.7, 86.1]	[71.7, 93.8]	[45.3, 74.9]	[48.5, 77.3]	[60.5, 87.1]	[61.2, 87.4]	[30.2, 59.9]				
	n positive	122	94	85	94	96	94	100	25				
	n borderline	-	-	-	5	5	12	7	3				
A+B	n negative	7	35	44	30	28	23	22	101				
	Sensitivity	94.6%	72.9%	65.9%	75.8%	77.4.%	80.34%	82.0%	19.8%				
	CI [%]	[89.1, 97.8]	[64.3 <i>,</i> 80.3]	[57.0, 74.0]	[67.3, 83.0]	[69.0, 8.4]	[72.0, 87.1]	[74.0, 88.3]	[13.3, 27.9]				
	n positive	0	0	0	0	1	0	1	0				
	n borderline	-	-	-	1	0	1	1	0				
С	n negative	42	42	42	41	41	41	40	42				
	Specificity	100%	100%	100%	100%	97.6%	100%	97.6%	100%				
	CI [%]	[91.6, 100]	[91.6, 100]	[91.6, 100]	[91.4, 100]	[87.4, 99.9]	[91.4, 100]	[87.4, 99.9]	[91.6, 100]				
	n positive	0	0	0	0	0	0	0	0				
	n borderline	-	-	-	0	0	0	0	0				
D	n negative	12	12	12	12	12	12	12	12				
	Cross- reactivity	none	none	none	none	none	none	none	none				

417

Table 3: Number of positive results and sensitivity (%) per infection phase based on 109 serum

419 samples from panels A+B taken later than ten days after onset of symptoms (dpso). For ELISA,

420 the number of borderline results are reported in brackets but were excluded for calculation of

421 the sensitivity.

	N samples	IIFT					ELISA										
Phase [dpso]		IgG		IgA		IgM		S1 IgG		QuantiVac S1 IgG		S1 IgA		NCP IgG		NCP IgM	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
11-20	29	28	96.6	27	93.1	28	96.6	19 (2)	70.4	20 (1)	71.4	24 (2)	88.9	25 (0)	86.2	14 (1)	50.0
21-60	31	31	100	31	100	27	87.1	28 (1)	93.3	28 (1)	93.3	24 (2)	82.8	30 (0)	96.8	4 (0)	12.9
>60	49	48	98.0	22	44.9	15	30.6	40 (2)	85.1	40 (3)	87.0	33 (8)	80.5	35 (6)	81.4	0 (2)	0.0
≥11	109	107	98.2	80	73.4	70	64.2	87 (5)	83.7	88 (5)	84.6	81 (12)	83.5	90 (6)	87.4	18 (3)	17.0

422 423

424 **Table 4:** Agreement between qualitative results of Anti-SARS-CoV-2 ELISA (IgG) and Anti-SARS-

425 CoV-2 QuantiVac ELISA (IgG) based on 183 serum samples (panels A, B, C and D).

n samples = 1	83	Anti-SARS-CoV-2 ELISA (IgG) positive borderline negative						
Anti-SARS-CoV-2	positive	93	3	1				
QuantiVac ELISA	borderline	0	3	2				
(IgG)	negative	1	0	80				
Positive agreement		98.9%						
Negative agreement	98.8%							
Total agreement		98.9%						

426 427

428 FIGURES

429



430 **Figure 1:** Longitudinal detection of SARS-CoV-2-specific antibody responses in serum samples

431 from panel A (25 patients, 82 samples) and B (17 patients, 47 samples, results of six samples

with unknown dpso are not displayed) with respect to phase of infection. Dpso: days after onset

- 433 of symptoms.
- 434



435

436 Figure 2: Correlation between semiquantitative results of Anti-SARS-CoV-2 ELISA (IgG) and
437 Anti-SARS-CoV-2 QuantiVac ELISA (IgG).